Another Monster Move in Biotech
$KOD with a huge gap up and massive volume today. Another explosive biotech move that brings $MRNA to mind.
Today’s catalyst: positive Phase 3 results from Kodiak’s DAYBREAK trial for wet age-related macular degeneration. Clinical results can change expectations for a company very quickly, and the chart shows that repricing in real time.
Looking further ahead, I think AI will help accelerate drug discovery and development, potentially opening the door to more biotech breakthroughs. If those advances translate into successful treatments, we could see more massive moves like this in the years ahead.
Biotech is an area worth watching.
